Key Highlights
- Strategic Partnership With Barcode Nanotech to Engineer Novel LNP Delivery for Aramchol: The collaboration leverages Barcode's specialized lipid nanoparticle platform to enhance the therapeutic reach of Galmed's proprietary SCD1 inhibitor in cardiovascular applications.
- Aramchol Is a Proprietary SCD1 Inhibitor Being Repositioned for Cardiovascular Medicine: The partnership expands the potential application of Aramchol beyond its prior development history, targeting the cardiovascular therapeutic area with an enhanced delivery mechanism.
- LNP Technology Could Meaningfully Improve Drug Delivery Efficiency and Target Tissue Access: Lipid nanoparticle delivery systems have demonstrated the ability to dramatically improve the bioavailability and tissue-specific delivery of pharmaceutical compounds, as validated by their use in mRNA COVID-19 vaccines.
Galmed Pharmaceuticals (NASDAQ: GLMD) established a strategic partnership with Barcode Nanotech to engineer a novel lipid nanoparticle delivery system for Aramchol, the company's proprietary stearoyl-CoA desaturase 1 (SCD1) inhibitor, with the initiative focused on leveraging Barcode's specialized delivery platform to enhance Aramchol's therapeutic reach in cardiovascular medicine.
Lipid nanoparticle technology has emerged as one of the most significant drug delivery innovations in modern pharmaceuticals, achieving mainstream validation through its use as the delivery mechanism for mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna (NASDAQ: MRNA). The ability of LNPs to encapsulate and protect drug molecules, enhance their bioavailability, and direct them to specific target tissues makes them a powerful tool for improving the therapeutic performance of compounds that face delivery challenges when administered through conventional routes.
Aramchol is a synthetic fatty acid-bile acid conjugate that functions as an SCD1 inhibitor — an enzyme involved in the synthesis of monounsaturated fatty acids that plays a role in lipid metabolism and has been implicated in metabolic liver disease, cardiovascular risk factors, and inflammation. The SCD1 inhibition mechanism makes Aramchol an interesting candidate for cardiovascular applications where modulation of lipid metabolism pathways is therapeutically relevant.
The partnership with Barcode Nanotech introduces a delivery engineering dimension to Aramchol's development that could potentially broaden its therapeutic applications beyond the compound's prior development history. By reformulating Aramchol within a purpose-engineered LNP system, Galmed aims to improve the compound's ability to reach target tissues with greater precision and at potentially lower systemic doses — characteristics that could improve the therapeutic index and clinical utility of the drug candidate.
For Galmed Pharmaceuticals (NASDAQ: GLMD), the partnership represents a strategic pivot that combines the company's existing proprietary compound with an external platform technology, a drug development model that has become increasingly common as pharmaceutical companies seek to extract additional value from existing drug candidates through delivery innovation.
Frequently Asked Questions (FAQs)






Please wait processing your request...